Table 1.
SCT, n = 59 (15.1%) | LCT, n = 331 (84.9%) | p-Value | |
---|---|---|---|
Age (median) (range) | 81 (26–100) | 81 (25–102) | 0.837 |
Sex (male:female) | 28:31 | 172:159 | 0.579 |
Cause of cholangitis | |||
Malignant stricture | 17 (28.8%) | 85 (25.7%) | 0.631 |
Bile duct stone | 36 (61.0%) | 216 (65.3%) | 0.556 |
Benign bile duct stricture | 3 (5.1%) | 8 (2.4%) | 0.223 |
Chronic pancreatitis | 1 (1.7%) | 4 (1.2%) | 0.562 |
Mirizzi syndrome | 0 (0.0%) | 9 (2.7%) | 0.366 |
Autoimmune pancreatitis | 1 (1.7%) | 1 (0.3%) | 0.28 |
Others | 1 (1.7%) | 8 (2.4%) | >0.99 |
Severity | |||
Mild | 32 (54.2%) | 151 (45.6%) | 0.258 |
Moderate | 27 (45.8%) | 180 (54.4%) | 0.258 |
Bil ≥ 5.0 (mg/dL) | 11 (18.6%) | 72 (21.8%) | 0.73 |
WBC < 4000, 12,000 < WBC (/μL) | 14 (23.7%) | 111 (33.5%) | 0.173 |
Alb < 3.0 (g/dL) | 18 (30.5%) | 100 (30.2%) | >0.99 |
NEWS (median) (range) | |||
On admission | 1 (0–7) | 1 (0–13) | 0.096 |
Just before ERCP | 1 (0–7) | 1 (0–13) | 0.159 |
48 h after ERCP | 0 (0–5) | 0 (0–6) | 0.429 |
Underlying disease | |||
CKD | 5 (8.5%) | 26 (7.9%) | 0.797 |
CHF | 2 (3.4%) | 34 (10.3%) | 0.139 |
LC | 3 (5.1%) | 15 (4.5%) | 0.743 |
DM | 8 (13.6%) | 62 (18.7%) | 0.461 |
Malignant tumor | 18 (30.5%) | 92 (27.8%) | 0.642 |
Patient background | |||
Nursing home | 7 (11.9%) | 70 (21.1%) | 0.112 |
Hemodialysis | 0 (0.0%) | 8 (2.4%) | 0.613 |
Gastrostomy | 1 (1.7%) | 1 (0.3%) | 0.28 |
Constant placement of urinary catheter | 0 (0%) | 2 (0.6%) | >0.99 |
Aspiration pneumonia | 0 (0%) | 7 (2.1%) | 0.601 |
Immunosuppressant | 0 (0%) | 6 (1.8%) | 0.597 |
Re-intervention to bile duct stent | 11 (18.6%) | 65 (19.6%) | >0.99 |
Some cases overlapped. SCT: short-course antibiotic therapy; LCT: long-course antibiotic therapy; Bil: bilirubin; WBC; white blood cells; Alb: albumin; NEWS: national early warning score; ERCP: endoscopic retrograde cholangiopancreatography; CKD: chronic kidney disease; CHF: chronic heart failure; LC: liver cirrhosis; DM: diabetes mellitus.